【摘要】：B-Myb是高度保守的轉(zhuǎn)錄因子Myb家族的成員之一,在有增殖能力的細(xì)胞中普遍表達(dá),并在細(xì)胞周期進(jìn)程中起到重要作用。有研究發(fā)現(xiàn),B-Myb在很多癌癥細(xì)胞中高表達(dá),如乳腺癌、肝細(xì)胞癌、神經(jīng)母細(xì)胞瘤等。這提示我們,B-Myb在癌癥的發(fā)生發(fā)展過程中可能發(fā)揮重要作用。迄今為止,B-Myb在肺癌中的表達(dá)及其作用機(jī)制尚不明確,故本論文主要研究B-Myb在肺癌組織樣本中的表達(dá)水平及其對(duì)肺癌細(xì)胞增殖、遷移侵襲、腫瘤形成的影響,并探究其分子機(jī)制。第一部分B-Myb過表達(dá)對(duì)肺癌細(xì)胞增殖、遷移侵襲及腫瘤形成的影響及機(jī)制研究目的:1.研究B-Myb在肺癌組織中表達(dá)與腫瘤的臨床病理特征之間的關(guān)系。2.檢測(cè)B-Myb過表達(dá)對(duì)肺癌細(xì)胞增殖、細(xì)胞周期、遷移侵襲、腫瘤形成的影響。3.初步闡明B-Myb過表達(dá)促進(jìn)肺癌細(xì)胞增殖、遷移侵襲及腫瘤形成的分子機(jī)制。方法:1.采用q RT-PCR、western blot及IHC檢測(cè)肺癌組織和正常肺組織中B-Myb的表達(dá)水平,統(tǒng)計(jì)分析B-Myb在肺癌組織中表達(dá)與腫瘤的臨床病理特征之間的關(guān)系。2.采用慢病毒感染的方法將目的基因B-Myb轉(zhuǎn)染到肺癌細(xì)胞中,建立B-Myb過表達(dá)的細(xì)胞模型;q RT-PCR和western blot檢測(cè)B-Myb及靶基因的m RNA和蛋白的表達(dá);CCK-8檢測(cè)細(xì)胞增殖;FCM檢測(cè)細(xì)胞周期;劃痕實(shí)驗(yàn)和Transwell檢測(cè)細(xì)胞遷移侵襲;裸鼠成瘤實(shí)驗(yàn)檢測(cè)肺癌細(xì)胞體內(nèi)成瘤能力。3.RNA-seq檢測(cè)肺癌細(xì)胞系H1299的B-Myb過表達(dá)組樣本與對(duì)照組樣本,GO富集分析和pathway富集分析篩選差異表達(dá)的基因及相關(guān)的信號(hào)通路。結(jié)果:1.檢測(cè)40例肺癌患者和7例對(duì)照正常肺組織c DNA芯片中B-Myb的m RNA表達(dá)水平,并通過IHC檢測(cè)69例肺癌患者及3例正常肺組織芯片中B-Myb的蛋白表達(dá)水平。統(tǒng)計(jì)分析顯示,肺癌組織中B-Myb的m RNA和蛋白表達(dá)水平均顯著高于正常肺組織,B-Myb的蛋白表達(dá)主要定位在細(xì)胞質(zhì)內(nèi),且B-Myb的表達(dá)量與腫瘤的大小、淋巴結(jié)轉(zhuǎn)移以及轉(zhuǎn)移癌等密切相關(guān)。進(jìn)一步檢測(cè)肺癌6個(gè)細(xì)胞系H1299、A549、H157、H446、H524和H460中B-Myb的m RNA表達(dá)水平,結(jié)果發(fā)現(xiàn)在肺癌細(xì)胞H1299和A549中B-Myb的m RNA表達(dá)相對(duì)較低。2.肺癌細(xì)胞系H1299和A549的B-Myb過表達(dá)細(xì)胞模型成功建立,且過表達(dá)組較對(duì)照組的目的基因B-Myb表達(dá)量至少高出4倍;CCK-8結(jié)果顯示,B-Myb過表達(dá)促進(jìn)肺癌細(xì)胞的增殖;FCM檢測(cè)結(jié)果顯示,B-Myb過表達(dá)組較對(duì)照組S期細(xì)胞數(shù)量顯著增加,且G1期細(xì)胞數(shù)量顯著減少;劃痕實(shí)驗(yàn)和Transwell遷移實(shí)驗(yàn)結(jié)果顯示,B-Myb過表達(dá)促進(jìn)肺癌細(xì)胞遷移;Transwell侵襲結(jié)果顯示,B-Myb過表達(dá)促進(jìn)肺癌細(xì)胞侵襲;體內(nèi)實(shí)驗(yàn)結(jié)果顯示,B-Myb過表達(dá)促進(jìn)肺癌細(xì)胞的腫瘤形成。3.RNA-seq的檢測(cè)和分析結(jié)果顯示,B-Myb過表達(dá)誘導(dǎo)390個(gè)基因的差異表達(dá),其中表達(dá)上調(diào)的有300個(gè)基因,表達(dá)下調(diào)的有90個(gè)基因。GO富集分析結(jié)果顯示差異表達(dá)的基因功能主要與細(xì)胞外基質(zhì)、生長(zhǎng)因子、細(xì)胞發(fā)育進(jìn)程有關(guān)。pathway富集分析結(jié)果顯示主要的信號(hào)通路包括細(xì)胞粘附因子通路、PI3K-Akt信號(hào)通路、癌癥通路及Ras信號(hào)通路。我們對(duì)部分差異表達(dá)的基因CCNA1、COL11A1、COL6A1、FN1、MMP2、NID1、FLT4、SPARC、INSR、IDH2、PDK3和IGFBP3進(jìn)行q RT-PCR檢測(cè),差異表達(dá)的趨勢(shì)與RNA-seq數(shù)據(jù)分析結(jié)果一致。進(jìn)一步western blot分析顯示,B-Myb過表達(dá)顯著提高ERK和Akt磷酸化水平,能夠激活ERK和Akt信號(hào)通路。結(jié)論:1.肺癌組織中B-Myb的m RNA水平和蛋白水平顯著高于正常肺組織,B-Myb的蛋白表達(dá)主要定位在細(xì)胞質(zhì)內(nèi),且B-Myb的表達(dá)量與腫瘤的大小、淋巴結(jié)轉(zhuǎn)移以及轉(zhuǎn)移癌等密切相關(guān)。2.體外實(shí)驗(yàn)顯示,B-Myb過表達(dá)能夠促進(jìn)細(xì)胞的增殖、細(xì)胞周期進(jìn)程和遷移侵襲;體內(nèi)實(shí)驗(yàn)顯示,B-Myb過表達(dá)能夠提高肺癌細(xì)胞的腫瘤形成能力。3.RNA-seq檢測(cè)分析結(jié)果顯示,差異表達(dá)的基因功能主要與細(xì)胞外基質(zhì)、生長(zhǎng)因子、細(xì)胞發(fā)育進(jìn)程有關(guān),對(duì)部分差異表達(dá)的基因進(jìn)行q RT-PCR檢測(cè),差異表達(dá)的趨勢(shì)與RNA-seq數(shù)據(jù)分析結(jié)果一致,pathway富集分析結(jié)果顯示主要的信號(hào)通路包括細(xì)胞粘附因子通路、PI3K-Akt信號(hào)通路、癌癥通路及Ras信號(hào)通路。Western blot分析顯示,B-Myb過表達(dá)顯著提高ERK和Akt磷酸化水平,能夠激活ERK和Akt信號(hào)通路,B-Myb能夠促進(jìn)肺癌的發(fā)生發(fā)展,或許部分是通過對(duì)ERK和Akt信號(hào)通路進(jìn)行調(diào)節(jié)。第二部分B-Myb干擾對(duì)肺癌細(xì)胞增殖、遷移侵襲及腫瘤形成的影響及機(jī)制研究目的:1.檢測(cè)B-Myb干擾對(duì)肺癌細(xì)胞增殖、周期、遷移侵襲、腫瘤形成等功能的影響。2.初步闡明B-Myb干擾抑制肺癌細(xì)胞增殖、遷移侵襲及腫瘤形成的分子機(jī)制。方法:1.采用慢病毒感染和瞬時(shí)轉(zhuǎn)染的方法將目的基因B-Myb的干擾序列轉(zhuǎn)染到肺癌細(xì)胞中,建立B-Myb干擾的細(xì)胞模型;q RT-PCR和western blot檢測(cè)B-Myb及靶基因的m RNA和蛋白的表達(dá);CCK-8檢測(cè)細(xì)胞增殖;FCM檢測(cè)細(xì)胞周期;劃痕和Transwell檢測(cè)細(xì)胞遷移侵襲;裸鼠成瘤檢測(cè)體內(nèi)成瘤能力。2.RNA-seq檢測(cè)H1299的B-Myb干擾組與對(duì)照組樣本,GO富集分析和pathway富集分析篩選出差異表達(dá)的基因及相關(guān)的信號(hào)通路。結(jié)果:1.肺癌細(xì)胞H1299和A549的B-Myb干擾模型成功建立,且B-Myb干擾效率大于60%;CCK-8結(jié)果顯示,B-Myb干擾抑制肺癌細(xì)胞的增殖;FCM檢測(cè)結(jié)果顯示,肺癌細(xì)胞B-Myb干擾后S期細(xì)胞數(shù)量減少,且G1期細(xì)胞數(shù)量顯著增加;劃痕和Transwell遷移結(jié)果顯示,B-Myb干擾抑制肺癌細(xì)胞遷移;Transwell侵襲結(jié)果顯示,B-Myb干擾抑制肺癌細(xì)胞侵襲;體內(nèi)實(shí)驗(yàn)結(jié)果顯示,B-Myb干擾抑制肺癌細(xì)胞的腫瘤形成。2.RNA-seq的檢測(cè)和分析結(jié)果顯示,B-Myb干擾誘導(dǎo)13362個(gè)基因差異表達(dá),其中包括6343個(gè)基因表達(dá)上調(diào),7019個(gè)基因表達(dá)下調(diào)。GO富集分析顯示差異表達(dá)的基因主要參與調(diào)控細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)、細(xì)胞周期、細(xì)胞增殖、細(xì)胞凋亡及遷移侵襲等功能,Pathway富集分析的主要是MAPK信號(hào)通路、凋亡和細(xì)胞周期相關(guān)信號(hào)通路。我們對(duì)部分差異表達(dá)的基因COL11A1、FLT4、SPARC、IDH2、PDK3和IGFBP3進(jìn)行q RT-PCR檢測(cè),差異表達(dá)的趨勢(shì)與RNA-seq數(shù)據(jù)分析結(jié)果一致。結(jié)論:1.體外實(shí)驗(yàn)顯示,B-Myb干擾能夠抑制肺癌細(xì)胞的增殖、遷移侵襲、且S期細(xì)胞減少;體內(nèi)實(shí)驗(yàn)顯示,B-Myb干擾能夠降低肺癌細(xì)胞的腫瘤形成能力。2.RNA-seq檢測(cè)并分析顯示,細(xì)胞外基質(zhì)、生長(zhǎng)因子、細(xì)胞發(fā)育進(jìn)程都存在基因表達(dá)的不同程度的下調(diào)。對(duì)部分差異表達(dá)的基因進(jìn)行q RT-PCR檢測(cè),差異表達(dá)的趨勢(shì)與RNA-seq數(shù)據(jù)分析結(jié)果一致,pathway富集分析結(jié)果顯示,主要的信號(hào)通路包括MAPK信號(hào)通路、凋亡和細(xì)胞周期相關(guān)信號(hào)通路。
[Abstract]:B-Myb is a member of the highly conserved transcription factor Myb family and is widely expressed in proliferating cells and plays an important role in the process of cell cycle. Some studies have found that B-Myb is highly expressed in many cancer cells, such as breast cancer, hepatocellular carcinoma, and neuroblastoma. This suggests that B-Myb is in the development of cancer. So far, the expression and mechanism of B-Myb in lung cancer are not clear. Therefore, this paper mainly studies the expression level of B-Myb in lung cancer tissue samples and its effect on lung cancer cell proliferation, migration and invasion, tumor formation, and explore its molecular mechanism. The first part of B-Myb overexpression on lung cancer The effect and mechanism of cell proliferation, migration, invasion and tumor formation: 1. study the relationship between the expression of B-Myb in lung cancer tissue and the clinicopathological features of tumor.2. detection of B-Myb overexpression on the proliferation, cell cycle, migration and invasion, and the effect of.3. on the proliferation of lung cancer cells and promoting the proliferation of lung cancer cells, migration and migration of lung cancer cells The molecular mechanism of invasion and tumor formation. Methods: 1. the expression of B-Myb in lung cancer tissues and normal lung tissues was detected by Q RT-PCR, Western blot and IHC. The relationship between the expression of B-Myb in lung cancer tissues and the clinicopathological features of the tumor was statistically analyzed.2. using the lentivirus infection method to transfect the target gene B-Myb to lung cancer. In the cell, B-Myb overexpressed cell model was established; Q RT-PCR and Western blot were used to detect the expression of M RNA and protein of B-Myb and target genes; CCK-8 detection of cell proliferation; FCM detection of cell cycle; scratch test and Transwell detection of cell migration and invasion; nude mice tumor testing detection of lung cancer cells in vivo tumorigenicity.3.RNA-seq detection of lung cancer cell lines 99 B-Myb overexpressed group samples and control group samples, GO enrichment analysis and pathway enrichment analysis were used to screen differentially expressed genes and related signaling pathways. Results: 1. detection of M RNA expression level of B-Myb in 40 cases of lung cancer patients and 7 normal lung tissue C DNA chips, and 69 cases of lung cancer and 3 normal lung tissue chips by IHC The protein expression level of middle B-Myb showed that the expression level of M RNA and protein of B-Myb in lung cancer tissues was significantly higher than that of normal lung tissue. The protein expression of B-Myb was mainly located in the cytoplasm, and the expression of B-Myb was closely related to the size of tumor, lymph node metastasis and metastatic carcinoma. Further detection of the 6 cell line of lung cancer H12 99, A549, H157, H446, H524 and H460 B-Myb m RNA expression level. The results showed that B-Myb M protein expression in lung cancer cells H1299 and A549 was relatively low, and the overexpressed cell model was successfully established, and the overexpressed group was at least 4 times higher than the control group. The expression of overexpression promoted the proliferation of lung cancer cells, and the results of FCM detection showed that the number of S phase cells in the B-Myb overexpression group was significantly increased and the number of G1 cells decreased significantly. The results of scratch test and Transwell migration showed that B-Myb overexpression promoted the migration of lung cancer cells; the result of Transwell invasion showed that the over expression of B-Myb promoted lung cancer cells. The results of the in vivo experiment showed that B-Myb overexpression promoted the tumor formation of.3.RNA-seq in lung cancer cells. The results showed that B-Myb overexpression induced the differential expression of 390 genes, of which 300 genes were up-regulated, and 90 gene.GO enrichment analysis showed that the function of differentially expressed genes was mainly related to the expression of down regulation. The results of extracellular matrix, growth factor, and cell development related to.Pathway enrichment analysis showed that the main signaling pathways included cell adhesion factor pathway, PI3K-Akt signaling pathway, cancer pathway and Ras signaling pathway. We expressed genes CCNA1, COL11A1, COL6A1, FN1, MMP2, NID1, FLT4, SPARC, INSR, INSR, INSR, INSR, SPARC, and CCNA1 The trend of differential expression was consistent with the results of RNA-seq data analysis. Further western blot analysis showed that B-Myb overexpression significantly increased the level of phosphorylation of ERK and Akt, and could activate ERK and Akt signaling pathways. Conclusion: 1. the B-Myb M levels and protein levels in lung cancer tissues are significantly higher than those of normal lung tissues. The protein expression of 1. lung cancer tissues is significantly higher than that of normal lung tissue. It is mainly located in the cytoplasm, and the expression of B-Myb is closely related to the size of tumor, lymph node metastasis and metastatic carcinoma. In vitro,.2. experiments show that overexpression of B-Myb can promote cell proliferation, cell cycle process and migration invasion. In vivo experiments show that B-Myb overexpression can improve the tumor formation ability of lung cancer cells.3.RNA-seq The results of detection analysis showed that the differentially expressed gene functions were mainly related to extracellular matrix, growth factor, cell development process, and Q RT-PCR detection for some differentially expressed genes. The trend of differential expression was consistent with the results of RNA-seq data analysis. Pathway enrichment analysis showed that the main signal pathways included cell adhesion factors. The pathway, PI3K-Akt signaling pathway, cancer pathway and Ras signaling pathway.Western blot analysis showed that B-Myb overexpression significantly increased the level of ERK and Akt phosphorylation, activated ERK and Akt signaling pathways, and B-Myb could promote the development of lung cancer, perhaps partly through the regulation of ERK and Akt signaling pathways. The second part interferes with lung cancer. Effects and mechanisms of cell proliferation, migration and invasion and tumor formation: 1. detection of the effects of B-Myb interference on proliferation, cycle, migration and invasion, and tumor formation of lung cancer cells..2. preliminarily clarifies the molecular mechanism of B-Myb interference to inhibit the proliferation, migration and invasion of lung cancer cells and the formation of tumor. Methods 1. use lentivirus infection and transient transformation. The staining method transfected the interference sequence of the target gene B-Myb into the lung cancer cells and established the B-Myb interference cell model; Q RT-PCR and Western blot detected the B-Myb and the expression of M RNA and protein of the target gene; CCK-8 detection of cell proliferation; FCM detection of cell cycle; scratch and Transwell detection of cell migration and invasion; tumor formation detection in nude mice. .2.RNA-seq detection of H1299 B-Myb interference group and control group samples, GO enrichment analysis and pathway enrichment analysis screened differentially expressed genes and related signaling pathways. Results: 1. the B-Myb interference model of H1299 and A549 in lung cancer cells was successfully established, and B-Myb interference efficiency was more than 60%; CCK-8 results showed that B-Myb interference inhibited lung cancer cells. The results of FCM detection showed that the number of S cells decreased and the number of G1 cells increased significantly after B-Myb interference, and the results of scratch and Transwell migration showed that B-Myb interference inhibited the migration of lung cancer cells; the results of Transwell invasion showed that B-Myb interference inhibited the invasion of lung cancer cells; in vivo experimental results showed that B-Myb interference inhibited lung cancer. The detection and analysis of the tumor formation of.2.RNA-seq showed that B-Myb interference induced 13362 differentially expressed genes, including 6343 gene expression up-regulated, 7019 gene expression down-regulation.GO enrichment analysis showed that the differentially expressed genes were mainly involved in regulating cell signal transduction, cell cycle, cell proliferation, cell apoptosis and migration invasion. MAPK signaling pathway, apoptosis and cell cycle related signal pathways were mainly analyzed by Pathway enrichment analysis. We detected Q RT-PCR in some differentially expressed genes COL11A1, FLT4, SPARC, IDH2, PDK3 and IGFBP3. The trend of differential expression was consistent with that of RNA-seq data analysis. Conclusion: 1. in vitro experiments showed that B-Myb interference could be suppressed. The proliferation, migration and invasion of lung cancer cells and the decrease of S phase cells; in vivo experiments showed that B-Myb interference could reduce the tumor formation ability of lung cancer cells by.2.RNA-seq detection and analysis showed that extracellular matrix, growth factor, and cell development process were all down regulated by different levels of gene expression. Q RT- for some differentially expressed genes PCR detection, the trend of differential expression is consistent with the results of RNA-seq data analysis. The results of pathway enrichment analysis show that the main signaling pathways include MAPK signaling pathway, apoptosis and cell cycle related signaling pathways.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 ;尼古丁加速肺癌細(xì)胞的增長(zhǎng)[J];中華醫(yī)學(xué)信息導(dǎo)報(bào);2003年09期

2 丁會(huì);孫曉艷;呂曉紅;;氯化汞對(duì)小鼠Lewis肺癌細(xì)胞周期的影響[J];吉林醫(yī)學(xué);2008年23期

3 ;腫瘤壞死因子受體在人類肺癌細(xì)胞和正常肺組織中的表達(dá)[J];國(guó)外醫(yī)學(xué).臨床生物化學(xué)與檢驗(yàn)學(xué)分冊(cè);1997年02期

4 鞏國(guó)亭,田立華,宋佃剛;兒童胸水查到肺癌細(xì)胞[J];上海醫(yī)學(xué)檢驗(yàn)雜志;1998年02期

5 王洪斌,熊海濤,蘇萬(wàn)芳,胡匡祜,黃志英;肺癌細(xì)胞形態(tài)量化和結(jié)構(gòu)特征的抽取[J];生物物理學(xué)報(bào);1999年01期

6 董強(qiáng)剛,江曉豐,沙慧芳,李魯萍,喬生軍,許凱黎;外周血循環(huán)中肺癌細(xì)胞的流式細(xì)胞儀定量分析[J];腫瘤;2000年01期

7 ;能殺死肺癌細(xì)胞的蛋白質(zhì)[J];醫(yī)學(xué)情報(bào)工作;2000年03期

8 周曉琦,劉劍平,李彤;化療藥物對(duì)原代肺癌細(xì)胞周期的影響[J];中國(guó)老年學(xué)雜志;2003年09期

9 王洪武,劉靜,段蘊(yùn)鈾,楊平地,黃友章,張燕群,周一欣,馮華松,顏霞,陸海英;氬氦靶向治療對(duì)肺癌細(xì)胞的滅活作用[J];海軍總醫(yī)院學(xué)報(bào);2003年02期

10 胡振紅,彭琪琳,汪君,傅祖紅,司斌,劉志遐;肺癌細(xì)胞在缺氧狀態(tài)下體外侵潤(rùn)力的變化及分子基礎(chǔ)[J];中國(guó)醫(yī)師雜志;2004年02期

相關(guān)會(huì)議論文 前10條

1 王洪武;黃友章;;凍融的肺癌細(xì)胞對(duì)骨髓樹突狀細(xì)胞的免疫調(diào)節(jié)作用[A];第一屆中國(guó)腫瘤靶向治療技術(shù)大會(huì)論文集[C];2003年

2 李智勇;劉增禮;吳錦昌;周俊東;申詠梅;勞勤華;;~(125)I-脫氧尿嘧啶核苷對(duì)肺癌細(xì)胞A549的殺傷作用[A];首屆全國(guó)分子核醫(yī)學(xué)暨分子影像學(xué)學(xué)術(shù)交流會(huì)資料匯編[C];2006年

3 李智勇;劉增禮;吳錦昌;周俊東;申詠梅;勞勤華;;~(125)I-脫氧尿嘧啶核苷對(duì)肺癌細(xì)胞A549的殺傷作用[A];第三屆全國(guó)核素顯像暨核素治療學(xué)術(shù)交流會(huì)論文匯編[C];2006年

4 王秦秦;姜平;李繼梅;唐睿珠;陳新明;;肺癌細(xì)胞相關(guān)蛋白分子實(shí)驗(yàn)研究[A];西部大開發(fā) 科教先行與可持續(xù)發(fā)展——中國(guó)科協(xié)2000年學(xué)術(shù)年會(huì)文集[C];2000年

5 謝慶軍;李季風(fēng);胡曉燕;;超級(jí)智能基因藥物對(duì)人惡性肺癌細(xì)胞的的抑制作用[A];中國(guó)細(xì)胞生物學(xué)學(xué)會(huì)醫(yī)學(xué)細(xì)胞生物學(xué)學(xué)術(shù)大會(huì)論文集[C];2006年

6 李鳴;黃承鈺;魏大鵬;;藥食兩用植物提取物影響肺癌細(xì)胞生長(zhǎng)的血清藥理學(xué)研究[A];中國(guó)營(yíng)養(yǎng)學(xué)會(huì)第九次全國(guó)營(yíng)養(yǎng)學(xué)術(shù)會(huì)議論文摘要匯編[C];2004年

7 馮華松;黃友章;段蘊(yùn)鈾;楊平地;李泳群;蘭雨;;氬氦刀冷凍處理的肺癌細(xì)胞增強(qiáng)樹突狀細(xì)胞誘導(dǎo)抗腫瘤效應(yīng)[A];第一屆中國(guó)腫瘤微創(chuàng)治療研討會(huì)暨中國(guó)抗癌協(xié)會(huì)腫瘤微創(chuàng)治療專業(yè)委員會(huì)成立大會(huì)論文集[C];2005年

8 馮華松;黃友章;段蘊(yùn)鈾;楊平地;蘭雨;李泳群;;氬氦刀冷凍處理的肺癌細(xì)胞可致敏人骨髓樹突狀細(xì)胞[A];第一屆中國(guó)腫瘤微創(chuàng)治療研討會(huì)暨中國(guó)抗癌協(xié)會(huì)腫瘤微創(chuàng)治療專業(yè)委員會(huì)成立大會(huì)論文集[C];2005年

9 喻倫銀;田鴻生;舒清波;劉銘球;夏東;;超氧化物歧化酶對(duì)A_(549)肺癌細(xì)胞一些生物學(xué)特性的影響[A];中國(guó)細(xì)胞生物學(xué)學(xué)會(huì)第五次會(huì)議論文摘要匯編[C];1992年

10 秦建軍;周清華;袁淑蘭;王艷萍;陳曉禾;何金濤;;逆癌酮對(duì)肺癌細(xì)胞的生長(zhǎng)抑制作用及其機(jī)理的初步研究[A];2000全國(guó)腫瘤學(xué)術(shù)大會(huì)論文集[C];2000年

相關(guān)重要報(bào)紙文章 前10條

1 記者 文俊 實(shí)習(xí)生 范敏 通訊員 羅芳;新技術(shù)“點(diǎn)亮”肺癌細(xì)胞[N];湖北日?qǐng)?bào);2014年

2 本版編輯邋夏洪平 編譯 復(fù)旦大學(xué)附屬中山醫(yī)院肺科 張新;肺癌細(xì)胞有“致命弱點(diǎn)”[N];健康報(bào);2008年

3 新訊;利用納米技術(shù)數(shù)分鐘可識(shí)別九成以上肺癌細(xì)胞[N];醫(yī)藥經(jīng)濟(jì)報(bào);2006年

4 特約記者 萬(wàn)初升;“核彈”自動(dòng)追擊肺癌細(xì)胞[N];家庭醫(yī)生報(bào);2005年

5 記者 何屹;英利用“冷凍療法”殺死肺癌細(xì)胞[N];科技日?qǐng)?bào);2005年

6 記者 何德功;阻遏肺癌擴(kuò)散[N];新華每日電訊;2002年

7 ;美證實(shí)SLC蛋白能殺死肺癌細(xì)胞[N];中國(guó)中醫(yī)藥報(bào);2000年

8 張?chǎng)稳A;肺癌有望實(shí)現(xiàn)早診斷[N];醫(yī)藥養(yǎng)生保健報(bào);2006年

9 楊茜;美發(fā)現(xiàn)肺癌化療藥物產(chǎn)生耐藥性機(jī)制[N];中國(guó)醫(yī)藥報(bào);2006年

10 ;美發(fā)現(xiàn)殺死肺癌的細(xì)胞蛋白[N];中國(guó)中醫(yī)藥報(bào);2002年

相關(guān)博士學(xué)位論文 前10條

1 門雪琳;肺癌組織與細(xì)胞中Cullin7的表達(dá)及臨床意義的研究[D];山東大學(xué);2015年

2 程傳樂;地錢素C誘導(dǎo)肺癌細(xì)胞死亡及抑制其侵襲轉(zhuǎn)移的機(jī)制研究[D];山東大學(xué);2015年

3 宋千成;microRNA-483-5p通過抑制RhoGDI1和ALCAM促進(jìn)肺癌細(xì)胞EMT、侵襲和轉(zhuǎn)移[D];南方醫(yī)科大學(xué);2013年

4 孔祥禎;酪氨酸代謝酶 HPD 在肺癌發(fā)生和發(fā)展中的作用及機(jī)制研宄[D];天津大學(xué);2015年

5 金景鵬;miR-517a-3p和miR-610對(duì)肺癌細(xì)胞增殖和侵襲能力的影響及其機(jī)制[D];吉林大學(xué);2016年

6 高海祥;miR-200c通過調(diào)節(jié)細(xì)胞上皮—間質(zhì)轉(zhuǎn)換改變肺癌細(xì)胞對(duì)克唑替尼的敏感性[D];河北醫(yī)科大學(xué);2016年

7 曹卓;miR-130a在肺癌中的表達(dá)及相關(guān)靶基因和肺癌發(fā)病機(jī)制探討[D];山東大學(xué);2016年

8 章衛(wèi)華;MLL2促進(jìn)肺癌A549細(xì)胞發(fā)生發(fā)展中的作用機(jī)制及蘿卜籽素抑制肺癌A549細(xì)胞的生物信息學(xué)研究[D];南昌大學(xué);2016年

9 姚媛菲;MARVELD1影響肺癌細(xì)胞基本生物學(xué)特征的分子機(jī)制[D];哈爾濱工業(yè)大學(xué);2016年

10 游良琨;Crizotinib誘導(dǎo)肺癌細(xì)胞保護(hù)性自噬及其機(jī)制研究[D];浙江大學(xué);2015年

相關(guān)碩士學(xué)位論文 前10條

1 李昊;血管內(nèi)皮生長(zhǎng)因子受體抑制劑DMH4對(duì)肺癌細(xì)胞增殖、遷移及凋亡的作用[D];河北大學(xué);2015年

2 王海洋;延伸復(fù)合體3（ELP3）對(duì)肺癌細(xì)胞A549的作用及調(diào)節(jié)機(jī)制研究[D];內(nèi)蒙古大學(xué);2015年

3 高愛迪;CT45A1基因促進(jìn)肺癌細(xì)胞侵襲和轉(zhuǎn)移的作用及其機(jī)制[D];蘇州大學(xué);2015年

4 楊周萍;GSTA1在肺癌細(xì)胞中的表達(dá)及其功能研究[D];廣東藥學(xué)院;2015年

5 陳碧玉;抑癌基因TCF21對(duì)肺癌細(xì)胞A549增殖和遷移的影響[D];貴陽(yáng)醫(yī)學(xué)院;2015年

6 李曉靜;KRAS基因表達(dá)對(duì)肺癌細(xì)胞糖酵解途徑的影響及機(jī)制[D];第三軍醫(yī)大學(xué);2015年

7 劉艷;VPS33B抑制肺癌細(xì)胞增殖，，遷移和侵襲[D];南方醫(yī)科大學(xué);2015年

8 楊杰;磷酸果糖激酶相關(guān)微小RNA影響腫瘤細(xì)胞糖代謝的機(jī)制研究[D];寧波大學(xué);2015年

9 林高陽(yáng);miR-26a靶向GSK-3β調(diào)控β-catenin信號(hào)通路增強(qiáng)肺癌細(xì)胞轉(zhuǎn)移潛能的機(jī)制研究[D];天津醫(yī)科大學(xué);2015年

10 鐘天飛;肺癌細(xì)胞STAT3分泌對(duì)裸鼠成瘤的影響及穿心蓮內(nèi)酯的調(diào)控作用[D];浙江中醫(yī)藥大學(xué);2016年

本文編號(hào)：2127197